Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.59 |
| ▸ | CCR2 | P41597 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12570805 | 0.92 | METAP2 (0.86) | METAP2CYP1A2CYP2C9MCL1CCR2 | |
| SCHEMBL12200971 | 0.88 | METAP2 (0.79) | METAP2CYP1A2CYP2C9MCL1ALDH1A1 | |
| SCHEMBL491833 | 0.87 | METAP2 (1.00) | METAP2CYP1A2CYP2C9ALDH1A1CCR2 | |
| SCHEMBL2003387 | 0.87 | METAP2 (0.77) | METAP2CYP1A2CYP2C9CCR2HTT | |
| SCHEMBL7322109 | 0.85 | METAP2 (0.73) | METAP2CYP1A2CYP2C9ALDH1A1HPGD | |
| SCHEMBL16495860 | 0.84 | METAP2 (0.73) | METAP2MCL1BCL2A1 | |
| SCHEMBL16496289 | 0.84 | METAP2 (0.75) | METAP2CYP1A2CYP2C9MCL1HTT | |
| SCHEMBL1688339 | 0.83 | METAP2 (0.71) | METAP2CYP1A2CYP2C9MCL1ALDH1A1 | |
| SCHEMBL12220857 | 0.83 | LMNA (0.81) | METAP2CYP1A2CYP2C9MCL1ALDH1A1 | |
| SCHEMBL6417385 | 0.82 | MEN1 (0.72) | METAP2MCL1ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | claimed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | claimed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | claimed |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | ZAFGEN, INC. | 2012-01-12 | — | — | US | disclosed |
| EP-1385820-B1 | ANTHRANILIC ACID AMIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS ANTIARRHYTHMIA AGENTS, AND PHARMACEUTICAL PREPARATIONS THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-10-12 | — | — | EP | disclosed |
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7332608-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-02-19 | — | — | US | disclosed |
| CN-101031541-A | 4-aminomethyl benzamidine derivatives and their use as factor VIIIa inhibitors | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | CN | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-7235690-B2 | Anthranilamides and methods of their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| EP-1791810-A1 | 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIA INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-24 | — | — | US | disclosed |
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2006027135-A1 | 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIIA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | AR, HTR3D, NR5A1 | METAP2 3615/4885CYP1A2 1914/4885CYP2C9 1517/4885 |
| US-20070117807-A1 | ANTHRANILAMIDES AND METHODS OF THEIR USE | KCNH1, KCNH2, KCNJ2 | METAP2 4099/4885CYP1A2 318/4885CYP2C9 1109/4885 |
| US-20120010290-A1 | Methods of Treating an Overweight or Obese Subject | METAP2, METAP1, ACER2 | METAP2 1/4885CYP1A2 156/4885CYP2C9 1398/4885 |
| US-20060116410-A1 | 4-Aminomethyl benzamidine derivatives | F7, HABP2, F12 | METAP2 275/4885CYP1A2 288/4885CYP2C9 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.